

Global Primary Biliary Cirrhosis Drug Market Insight and Forecast to 2026

<https://marketpublishers.com/r/GCE0489DF45DEN.html>

Date: August 2020

Pages: 138

Price: US\$ 2,350.00 (Single User License)

ID: GCE0489DF45DEN

Abstracts

The research team projects that the Primary Biliary Cirrhosis Drug market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

AlbireoPharma

MediGene AG

Enanta Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Johnson & Johnson

Dr. Falk Pharma GmbH

Virobay Inc.

Intercept Pharmaceuticals, Inc.

GlaxoSmithKline Plc

NGM Biopharmaceuticals, Inc.

By Type

Budesonide

FFP-104

GSK-2330672

MBX-8025

NGM-282

Others

By Application

Clinic

Hospital

Others

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

South Asia

India

Southeast Asia

Indonesia

Thailand

Singapore

Middle East

Turkey

Saudi Arabia

Iran

Africa

Nigeria

South Africa

Oceania

Australia

South America

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective

organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Primary Biliary Cirrhosis Drug 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2019.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2021-2026. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers majority Product Types in the Primary Biliary Cirrhosis Drug Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Primary Biliary Cirrhosis Drug Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with

the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Primary Biliary Cirrhosis Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Primary Biliary Cirrhosis Drug Revenue

1.4 Market Analysis by Type

1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Budesonide

1.4.3 FFP-104

1.4.4 GSK-2330672

1.4.5 MBX-8025

1.4.6 NGM-282

1.4.7 Others

1.5 Market by Application

1.5.1 Global Primary Biliary Cirrhosis Drug Market Share by Application: 2021-2026

1.5.2 Clinic

1.5.3 Hospital

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.6.2 Covid-19 Impact: Commodity Prices Indices

1.6.3 Covid-19 Impact: Global Major Government Policy

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Primary Biliary Cirrhosis Drug Market Perspective (2021-2026)

2.2 Primary Biliary Cirrhosis Drug Growth Trends by Regions

2.2.1 Primary Biliary Cirrhosis Drug Market Size by Regions: 2015 VS 2021 VS 2026

2.2.2 Primary Biliary Cirrhosis Drug Historic Market Size by Regions (2015-2020)

2.2.3 Primary Biliary Cirrhosis Drug Forecasted Market Size by Regions (2021-2026)

3 MARKET COMPETITION BY MANUFACTURERS

3.1 Global Primary Biliary Cirrhosis Drug Production Capacity Market Share by Manufacturers (2015-2020)

3.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2015-2020)

3.3 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2015-2020)

4 PRIMARY BILIARY CIRRHOSIS DRUG PRODUCTION BY REGIONS

4.1 North America

4.1.1 North America Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.1.2 Primary Biliary Cirrhosis Drug Key Players in North America (2015-2020)

4.1.3 North America Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)

4.1.4 North America Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

4.2 East Asia

4.2.1 East Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.2.2 Primary Biliary Cirrhosis Drug Key Players in East Asia (2015-2020)

4.2.3 East Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)

4.2.4 East Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

4.3 Europe

4.3.1 Europe Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.3.2 Primary Biliary Cirrhosis Drug Key Players in Europe (2015-2020)

4.3.3 Europe Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)

4.3.4 Europe Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

4.4 South Asia

4.4.1 South Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.4.2 Primary Biliary Cirrhosis Drug Key Players in South Asia (2015-2020)

4.4.3 South Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)

4.4.4 South Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

4.5 Southeast Asia

4.5.1 Southeast Asia Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.5.2 Primary Biliary Cirrhosis Drug Key Players in Southeast Asia (2015-2020)

4.5.3 Southeast Asia Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)

4.5.4 Southeast Asia Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

4.6 Middle East

4.6.1 Middle East Primary Biliary Cirrhosis Drug Market Size (2015-2026)

4.6.2 Primary Biliary Cirrhosis Drug Key Players in Middle East (2015-2020)

- 4.6.3 Middle East Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
- 4.6.4 Middle East Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
- 4.7 Africa
 - 4.7.1 Africa Primary Biliary Cirrhosis Drug Market Size (2015-2026)
 - 4.7.2 Primary Biliary Cirrhosis Drug Key Players in Africa (2015-2020)
 - 4.7.3 Africa Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
 - 4.7.4 Africa Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
- 4.8 Oceania
 - 4.8.1 Oceania Primary Biliary Cirrhosis Drug Market Size (2015-2026)
 - 4.8.2 Primary Biliary Cirrhosis Drug Key Players in Oceania (2015-2020)
 - 4.8.3 Oceania Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
 - 4.8.4 Oceania Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
- 4.9 South America
 - 4.9.1 South America Primary Biliary Cirrhosis Drug Market Size (2015-2026)
 - 4.9.2 Primary Biliary Cirrhosis Drug Key Players in South America (2015-2020)
 - 4.9.3 South America Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
 - 4.9.4 South America Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
- 4.10 Rest of the World
 - 4.10.1 Rest of the World Primary Biliary Cirrhosis Drug Market Size (2015-2026)
 - 4.10.2 Primary Biliary Cirrhosis Drug Key Players in Rest of the World (2015-2020)
 - 4.10.3 Rest of the World Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
 - 4.10.4 Rest of the World Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)

5 PRIMARY BILIARY CIRRHOSIS DRUG CONSUMPTION BY REGION

- 5.1 North America
 - 5.1.1 North America Primary Biliary Cirrhosis Drug Consumption by Countries
 - 5.1.2 United States
 - 5.1.3 Canada
 - 5.1.4 Mexico
- 5.2 East Asia
 - 5.2.1 East Asia Primary Biliary Cirrhosis Drug Consumption by Countries
 - 5.2.2 China
 - 5.2.3 Japan
 - 5.2.4 South Korea

5.3 Europe

5.3.1 Europe Primary Biliary Cirrhosis Drug Consumption by Countries

5.3.2 Germany

5.3.3 United Kingdom

5.3.4 France

5.3.5 Italy

5.3.6 Russia

5.3.7 Spain

5.3.8 Netherlands

5.3.9 Switzerland

5.3.10 Poland

5.4 South Asia

5.4.1 South Asia Primary Biliary Cirrhosis Drug Consumption by Countries

5.4.2 India

5.4.3 Pakistan

5.4.4 Bangladesh

5.5 Southeast Asia

5.5.1 Southeast Asia Primary Biliary Cirrhosis Drug Consumption by Countries

5.5.2 Indonesia

5.5.3 Thailand

5.5.4 Singapore

5.5.5 Malaysia

5.5.6 Philippines

5.5.7 Vietnam

5.5.8 Myanmar

5.6 Middle East

5.6.1 Middle East Primary Biliary Cirrhosis Drug Consumption by Countries

5.6.2 Turkey

5.6.3 Saudi Arabia

5.6.4 Iran

5.6.5 United Arab Emirates

5.6.6 Israel

5.6.7 Iraq

5.6.8 Qatar

5.6.9 Kuwait

5.6.10 Oman

5.7 Africa

5.7.1 Africa Primary Biliary Cirrhosis Drug Consumption by Countries

5.7.2 Nigeria

- 5.7.3 South Africa
- 5.7.4 Egypt
- 5.7.5 Algeria
- 5.7.6 Morocco
- 5.8 Oceania
 - 5.8.1 Oceania Primary Biliary Cirrhosis Drug Consumption by Countries
 - 5.8.2 Australia
 - 5.8.3 New Zealand
- 5.9 South America
 - 5.9.1 South America Primary Biliary Cirrhosis Drug Consumption by Countries
 - 5.9.2 Brazil
 - 5.9.3 Argentina
 - 5.9.4 Columbia
 - 5.9.5 Chile
 - 5.9.6 Venezuela
 - 5.9.7 Peru
 - 5.9.8 Puerto Rico
 - 5.9.9 Ecuador
- 5.10 Rest of the World
 - 5.10.1 Rest of the World Primary Biliary Cirrhosis Drug Consumption by Countries
 - 5.10.2 Kazakhstan

6 PRIMARY BILIARY CIRRHOSIS DRUG SALES MARKET BY TYPE (2015-2026)

- 6.1 Global Primary Biliary Cirrhosis Drug Historic Market Size by Type (2015-2020)
- 6.2 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Type (2021-2026)

7 PRIMARY BILIARY CIRRHOSIS DRUG CONSUMPTION MARKET BY APPLICATION(2015-2026)

- 7.1 Global Primary Biliary Cirrhosis Drug Historic Market Size by Application (2015-2020)
- 7.2 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Application (2021-2026)

8 COMPANY PROFILES AND KEY FIGURES IN PRIMARY BILIARY CIRRHOSIS DRUG BUSINESS

- 8.1 AlbireoPharma

- 8.1.1 AlbireoPharma Company Profile
- 8.1.2 AlbireoPharma Primary Biliary Cirrhosis Drug Product Specification
- 8.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.2 MediGene AG
 - 8.2.1 MediGene AG Company Profile
 - 8.2.2 MediGene AG Primary Biliary Cirrhosis Drug Product Specification
 - 8.2.3 MediGene AG Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.3 Enanta Pharmaceuticals, Inc.
 - 8.3.1 Enanta Pharmaceuticals, Inc. Company Profile
 - 8.3.2 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification
 - 8.3.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.4 CymaBay Therapeutics, Inc.
 - 8.4.1 CymaBay Therapeutics, Inc. Company Profile
 - 8.4.2 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Specification
 - 8.4.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.5 Johnson & Johnson
 - 8.5.1 Johnson & Johnson Company Profile
 - 8.5.2 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Specification
 - 8.5.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.6 Dr. Falk Pharma GmbH
 - 8.6.1 Dr. Falk Pharma GmbH Company Profile
 - 8.6.2 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Specification
 - 8.6.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.7 Virobay Inc.
 - 8.7.1 Virobay Inc. Company Profile
 - 8.7.2 Virobay Inc. Primary Biliary Cirrhosis Drug Product Specification
 - 8.7.3 Virobay Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.8 Intercept Pharmaceuticals, Inc.
 - 8.8.1 Intercept Pharmaceuticals, Inc. Company Profile
 - 8.8.2 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification

8.8.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.9 GlaxoSmithKline Plc

8.9.1 GlaxoSmithKline Plc Company Profile

8.9.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Specification

8.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.10 NGM Biopharmaceuticals, Inc.

8.10.1 NGM Biopharmaceuticals, Inc. Company Profile

8.10.2 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Specification

8.10.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)

9 PRODUCTION AND SUPPLY FORECAST

9.1 Global Forecasted Production of Primary Biliary Cirrhosis Drug (2021-2026)

9.2 Global Forecasted Revenue of Primary Biliary Cirrhosis Drug (2021-2026)

9.3 Global Forecasted Price of Primary Biliary Cirrhosis Drug (2015-2026)

9.4 Global Forecasted Production of Primary Biliary Cirrhosis Drug by Region (2021-2026)

9.4.1 North America Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.2 East Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.3 Europe Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.4 South Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.5 Southeast Asia Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.6 Middle East Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.7 Africa Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.8 Oceania Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.9 South America Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2021-2026)

9.4.10 Rest of the World Primary Biliary Cirrhosis Drug Production, Revenue Forecast

(2021-2026)

9.5 Forecast by Type and by Application (2021-2026)

9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type

(2021-2026)

9.5.2 Global Forecasted Consumption of Primary Biliary Cirrhosis Drug by Application

(2021-2026)

10 CONSUMPTION AND DEMAND FORECAST

10.1 North America Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.2 East Asia Market Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.3 Europe Market Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.4 South Asia Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.5 Southeast Asia Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.6 Middle East Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.7 Africa Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.8 Oceania Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.9 South America Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

10.10 Rest of the world Forecasted Consumption of Primary Biliary Cirrhosis Drug by Country

11 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS

11.1 Marketing Channel

11.2 Primary Biliary Cirrhosis Drug Distributors List

11.3 Primary Biliary Cirrhosis Drug Customers

12 INDUSTRY TRENDS AND GROWTH STRATEGY

12.1 Market Top Trends

12.2 Market Drivers

12.3 Market Challenges

12.4 Porter's Five Forces Analysis

12.5 Primary Biliary Cirrhosis Drug Market Growth Strategy

13 ANALYST'S VIEWPOINTS/CONCLUSIONS

14 APPENDIX

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Global Primary Biliary Cirrhosis Drug Market Share by Type: 2020 VS 2026

Table 2. Budesonide Features

Table 3. FFP-104 Features

Table 4. GSK-2330672 Features

Table 5. MBX-8025 Features

Table 6. NGM-282 Features

Table 7. Others Features

Table 11. Global Primary Biliary Cirrhosis Drug Market Share by Application: 2020 VS 2026

Table 12. Clinic Case Studies

Table 13. Hospital Case Studies

Table 14. Others Case Studies

Table 21. Commodity Prices-Metals Price Indices

Table 22. Commodity Prices- Precious Metal Price Indices

Table 23. Commodity Prices- Agricultural Raw Material Price Indices

Table 24. Commodity Prices- Food and Beverage Price Indices

Table 25. Commodity Prices- Fertilizer Price Indices

Table 26. Commodity Prices- Energy Price Indices

Table 27. G20+: Economic Policy Responses to COVID-19

Table 28. Primary Biliary Cirrhosis Drug Report Years Considered

Table 29. Global Primary Biliary Cirrhosis Drug Market Size YoY Growth 2021-2026 (US\$ Million)

Table 30. Global Primary Biliary Cirrhosis Drug Market Share by Regions: 2021 VS 2026

Table 31. North America Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 32. East Asia Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 33. Europe Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 34. South Asia Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 35. Southeast Asia Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 36. Middle East Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026) (US\$ Million)

Table 37. Africa Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026)
(US\$ Million)

Table 38. Oceania Primary Biliary Cirrhosis Drug Market Size YoY Growth (2015-2026)
(US\$ Million)

Table 39. South America Primary Biliary Cirrhosis Drug Market Size YoY Growth
(2015-2026) (US\$ Million)

Table 40. Rest of the World Primary Biliary Cirrhosis Drug Market Size YoY Growth
(2015-2026) (US\$ Million)

Table 41. North America Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 42. East Asia Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 43. Europe Primary Biliary Cirrhosis Drug Consumption by Region (2015-2020)

Table 44. South Asia Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 45. Southeast Asia Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 46. Middle East Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 47. Africa Primary Biliary Cirrhosis Drug Consumption by Countries (2015-2020)

Table 48. Oceania Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 49. South America Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 50. Rest of the World Primary Biliary Cirrhosis Drug Consumption by Countries
(2015-2020)

Table 51. AlbireoPharma Primary Biliary Cirrhosis Drug Product Specification

Table 52. MediGene AG Primary Biliary Cirrhosis Drug Product Specification

Table 53. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
Specification

Table 54. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product
Specification

Table 55. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Specification

Table 56. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Specification

Table 57. Virobay Inc. Primary Biliary Cirrhosis Drug Product Specification

Table 58. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
Specification

Table 59. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Specification

Table 60. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product

Specification

Table 101. Global Primary Biliary Cirrhosis Drug Production Forecast by Region (2021-2026)

Table 102. Global Primary Biliary Cirrhosis Drug Sales Volume Forecast by Type (2021-2026)

Table 103. Global Primary Biliary Cirrhosis Drug Sales Volume Market Share Forecast by Type (2021-2026)

Table 104. Global Primary Biliary Cirrhosis Drug Sales Revenue Forecast by Type (2021-2026)

Table 105. Global Primary Biliary Cirrhosis Drug Sales Revenue Market Share Forecast by Type (2021-2026)

Table 106. Global Primary Biliary Cirrhosis Drug Sales Price Forecast by Type (2021-2026)

Table 107. Global Primary Biliary Cirrhosis Drug Consumption Volume Forecast by Application (2021-2026)

Table 108. Global Primary Biliary Cirrhosis Drug Consumption Value Forecast by Application (2021-2026)

Table 109. North America Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 110. East Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 111. Europe Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 112. South Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 113. Southeast Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 114. Middle East Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 115. Africa Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 116. Oceania Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 117. South America Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 118. Rest of the world Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026 by Country

Table 119. Primary Biliary Cirrhosis Drug Distributors List

Table 120. Primary Biliary Cirrhosis Drug Customers List

Table 121. Porter's Five Forces Analysis

Table 122. Key Executives Interviewed

Figure 1. North America Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 2. North America Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 3. United States Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 4. Canada Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 5. Mexico Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 6. East Asia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 7. East Asia Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 8. China Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 9. Japan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 10. South Korea Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 11. Europe Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 12. Europe Primary Biliary Cirrhosis Drug Consumption Market Share by Region in 2020

Figure 13. Germany Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 14. United Kingdom Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 15. France Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 16. Italy Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 17. Russia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 18. Spain Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 19. Netherlands Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 20. Switzerland Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 21. Poland Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 22. South Asia Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 23. South Asia Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 24. India Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 25. Pakistan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 26. Bangladesh Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 27. Southeast Asia Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 28. Southeast Asia Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 29. Indonesia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 30. Thailand Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 31. Singapore Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 32. Malaysia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 33. Philippines Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 34. Vietnam Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 35. Myanmar Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 36. Middle East Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 37. Middle East Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 38. Turkey Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 39. Saudi Arabia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 40. Iran Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 41. United Arab Emirates Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 42. Israel Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 43. Iraq Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 44. Qatar Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 45. Kuwait Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 46. Oman Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 47. Africa Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 48. Africa Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 49. Nigeria Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 50. South Africa Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 51. Egypt Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 52. Algeria Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 53. Morocco Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 54. Oceania Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 55. Oceania Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 56. Australia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 57. New Zealand Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 58. South America Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 59. South America Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 60. Brazil Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 61. Argentina Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 62. Columbia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 63. Chile Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 64. Venezuelal Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 65. Peru Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 66. Puerto Rico Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 67. Ecuador Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 68. Rest of the World Primary Biliary Cirrhosis Drug Consumption and Growth Rate

Figure 69. Rest of the World Primary Biliary Cirrhosis Drug Consumption Market Share by Countries in 2020

Figure 70. Kazakhstan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2015-2020)

Figure 71. Global Primary Biliary Cirrhosis Drug Production Capacity Growth Rate Forecast (2021-2026)

Figure 72. Global Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 73. Global Primary Biliary Cirrhosis Drug Price and Trend Forecast (2015-2026)

Figure 74. North America Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 75. North America Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 76. East Asia Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 77. East Asia Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 78. Europe Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 79. Europe Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 80. South Asia Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 81. South Asia Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 82. Southeast Asia Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 83. Southeast Asia Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 84. Middle East Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 85. Middle East Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 86. Africa Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 87. Africa Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 88. Oceania Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 89. Oceania Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 90. South America Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 91. South America Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 92. Rest of the World Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2021-2026)

Figure 93. Rest of the World Primary Biliary Cirrhosis Drug Revenue Growth Rate Forecast (2021-2026)

Figure 94. North America Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 95. East Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 96. Europe Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 97. South Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 98. Southeast Asia Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 99. Middle East Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 100. Africa Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 101. Oceania Primary Biliary Cirrhosis Drug Consumption Forecast 2021-2026

Figure 102. South America Primary Biliary Cirrhosis Drug Consumption Forecast

2021-2026

Figure 103. Rest of the world Primary Biliary Cirrhosis Drug Consumption Forecast

2021-2026

Figure 104. Channels of Distribution

Figure 105. Distributors Profiles

I would like to order

Product name: Global Primary Biliary Cirrhosis Drug Market Insight and Forecast to 2026

Product link: <https://marketpublishers.com/r/GCE0489DF45DEN.html>

Price: US\$ 2,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCE0489DF45DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970